| scholarly article | Q13442814 |
| P356 | DOI | 10.4049/JIMMUNOL.166.5.3499 |
| P698 | PubMed publication ID | 11207309 |
| P2093 | author name string | S H Kim | |
| S Kim | |||
| P D Robbins | |||
| C H Evans | |||
| S C Ghivizzani | |||
| T Oligino | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 3499-505 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 | |
| P478 | volume | 166 |
| Q36011349 | A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice |
| Q84007460 | A role for anti-CD45RB monoclonal antibody treatment upon dendritic cells |
| Q34382930 | A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. |
| Q36576356 | AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice |
| Q36657882 | Activating and inhibitory FcgammaRs in autoimmune disorders. |
| Q35172114 | Adoptive cellular gene therapy of autoimmune disease |
| Q39587262 | Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model |
| Q42457419 | An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint |
| Q33924632 | An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis |
| Q35605653 | Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. |
| Q36622653 | Application of cellular gene therapy for rheumatoid arthritis |
| Q53003745 | Arthritis induced with cartilage-specific antibodiesis IL-4-dependent. |
| Q33980867 | CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease |
| Q38758281 | CD11b regulates the Treg/Th17 balance in murine arthritis via IL-6. |
| Q42326335 | Characterization of inhibitory T cells induced by an analog of type II collagen in an HLA-DR1 humanized mouse model of autoimmune arthritis |
| Q35090336 | Clinical potential and challenges of using genetically modified cells for articular cartilage repair |
| Q45883065 | Collagen II-pulsed antigen-presenting cells genetically modified to secrete IL-4 down-regulate collagen-induced arthritis |
| Q92422540 | Combination Therapy of Mesenchymal Stromal Cells and Interleukin-4 Attenuates Rheumatoid Arthritis in a Collagen-Induced Murine Model |
| Q79248342 | Comparative evaluation of CC chemokine-induced migration of murine CD8α+ and CD8α− dendritic cells and their in vivo trafficking |
| Q35116303 | Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? |
| Q35843248 | DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice |
| Q34982085 | Dendritic cell control of tolerogenic responses |
| Q45858420 | Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection |
| Q35161161 | Dendritic cells, T cell tolerance and therapy of adverse immune reactions |
| Q34740521 | Dendritic cells, tolerance induction and transplant outcome |
| Q35583516 | Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction |
| Q34319943 | Designer dendritic cells for tolerance induction: guided not misguided missiles |
| Q41754216 | Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells |
| Q45863651 | Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein |
| Q64378279 | Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive |
| Q24805400 | Future of adenoviruses in the gene therapy of arthritis |
| Q38526206 | Gene Therapy for Cartilage Repair |
| Q42608288 | Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. |
| Q35122176 | Gene therapy for arthritis |
| Q34526913 | Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators |
| Q24796801 | Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? |
| Q34418057 | Gene therapy in autoimmune disease |
| Q35122173 | Gene therapy in nonhuman primate models of human autoimmune disease. |
| Q37207021 | Gene therapy of the rheumatic diseases: 1998 to 2008. |
| Q41180997 | Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. |
| Q26764855 | Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications |
| Q38682156 | Harnessing the properties of dendritic cells in the pursuit of immunological tolerance |
| Q41987472 | High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. |
| Q62748555 | How do dendritic cells prevent autoimmunity? |
| Q64228779 | Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies |
| Q35882794 | Immunosuppressive exosomes: a new approach for treating arthritis |
| Q24673314 | Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors |
| Q40715343 | Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs |
| Q24793412 | Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid |
| Q40551497 | Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis |
| Q42110748 | LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. |
| Q46078304 | Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues. |
| Q34637340 | Lessons from animal models of arthritis |
| Q45863664 | Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis |
| Q37262385 | Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells |
| Q28066545 | Modulation of Immune Responses by Exosomes Derived from Antigen-Presenting Cells |
| Q35688328 | On the TRAIL of an arthritis cure |
| Q33713231 | Orthopedic gene therapy in 2008. |
| Q45864537 | Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist |
| Q37110557 | Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. |
| Q27006748 | Regulation of immune responses by extracellular vesicles |
| Q35617341 | Role of gene therapy in tissue engineering procedures in rheumatology: the use of animal models |
| Q42086872 | T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. |
| Q41963922 | T cells stimulated with an analog peptide of type II collagen require the Fc receptor γ-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice. |
| Q27687098 | Targeting dendritic cell function during systemic autoimmunity to restore tolerance |
| Q24813121 | The 3rd International Meeting on Gene Therapy in Rheumatology and Orthopaedics |
| Q45869577 | The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
| Q34338355 | Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? |
| Q37929646 | Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives |
| Q37826217 | Tolerogenic dendritic cells and their potential applications |
Search more.